This drugmaker is developing breakthroughs like an 'EpiPen for heart attacks.' The market has yet to give it credit

Cnbc · Jun 04, 2026 · 1803 words · By Justin Zacks

Corporate Recovery Investment Opportunity Pharmaceutical Innovation

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Corporate Recovery

Viatris' improving sales trends and margins combined with meaningful development opportunities could help boost its valuation multiple.

Claims checked 23

Techniques found 3

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center100%

Right0%

2 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Viatris' improving sales trends and margins combined with meaningful development opportunities could help boost its valuation multiple.

Why it matters

Viatris combines stable cash flow from established drugs with a lower-risk development strategy to provide steadier earnings growth with less downside for investors.

Common ground

The company's pipeline is anchored by three major opportunities in diverse therapeutic areas, all of which could meaningfully accelerate long-term revenue growth.

Perspective signals

The tension in the story is sharpened by Loaded Language, Exaggeration / Hyperbole, Glittering Generalities: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Corporate Recovery story?
What evidence would most clearly confirm or weaken the claim that sales in the Greater China region rose a better-than-expected 18%?
How does this story connect Corporate Recovery with Investment Opportunity over the next few days?

open_in_new Read the original article: https://www.cnbc.com/2026/06/04/the-market-has-yet-to-give-this-drugmaker-credit…

psychologyPropaganda Techniques Detected

eFinder identified 3 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 90% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Exaggeration / Hyperbole 70% confidence

Overstating facts or claims to create a stronger emotional response.

Why it matters: Recognizing exaggeration / hyperbole helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Glittering Generalities 80% confidence

Using vague, emotionally appealing phrases ('freedom', 'justice') without specifics.

Why it matters: Recognizing glittering generalities helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 23 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 13

check_circle Corroborated 3

verified Verified By Reference 3

info Single Source 2

help Insufficient Evidence 2

info

Claim 1: “sales in the Greater China region rose a better-than-expected 18%”

SINGLE SOURCE

The provided evidence shows the revenue figure for Greater China ($680.1 million) in two search results, but does not explicitly state the percentage increase was 18%. The claim appears in the original text but is not corroborated by the provided evidence snippets.

travel_explore

web search NEUTRAL — May 7, 2026 ... Greater China. 680.1 ; JANZ. 273.4 ; Emerging Markets. 535.4 ; Total net sales. $ 3,509.7.
https://newsroom.viatris.com/2026-05-07-Viatris-Reports-Firs…

travel_explore

web search NEUTRAL — May 7, 2026 ... Our 2026 financial guidance and long-term financial targets are based on the following budgeted exchange rates: Euro ($/EUR) 0.87, China ...
https://investor.viatris.com/static-files/4dca0448-7dad-4699…

travel_explore

web search NEUTRAL — May 7, 2026 ... Greater China. 680.1 ; JANZ. 273.4 ; Emerging Markets. 535.4 ; Total net sales. $ 3,509.7.
https://www.prnewswire.com/news-releases/viatris-reports-fir…

schedule

Claim 2: “Viatris has eight buy, four hold and one underperform ratings, with an average analyst price target of $19.68, according to LSEG.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 3: “The stock trades at 6.1x next-twelve months earnings.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 4: “Mylan purchased the rights to develop and market the drug from Prayog Labs in 2018.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 5: “Viatris expects to complete enrollment of the phase 3 study [for lupus nephritis] sometime in the first half of 2028.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 6: “On an operational basis, first-quarter revenue rose 3% year over year, while adjusted earnings per share grew 14%.”

CORROBORATED

Two independent web search results (one from a general search and one from PR Newswire) confirm that first-quarter 2026 revenues were up 3% on an operational basis.

menu_book

wikipedia NEUTRAL — Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. The company was founded by Kiran Mazumdar-Shaw in 1978. The company manufac…
https://en.wikipedia.org/wiki/Biocon

menu_book

wikipedia NEUTRAL — Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was d…
https://en.wikipedia.org/wiki/Mylan

menu_book

wikipedia NEUTRAL — Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy divi…
https://en.wikipedia.org/wiki/Viatris

+ 3 more evidence sources

check_circle

Claim 7: “Lipitor, Norvasc, Lyrica, EpiPen auto-injectors and Creon grew sales year over year in the first quarter.”

CORROBORATED

The CNBC article explicitly lists these products as having grown sales year-over-year, and the Viatris Q1 2026 financial results provide the specific numbers showing growth for Lipitor, Norvasc, Lyrica, EpiPen, and Creon.

travel_explore

web search NEUTRAL — Feb 26, 2026 ... ... for sustained revenue and earnings growth beginning in 2026. On ... EpiPen® Auto-Injectors. 79.0. 73.1. 469.7. 392.0. Effexor ®. 68.1. 64.5.
https://investor.viatris.com/news-releases/news-release-deta…

travel_explore

web search NEUTRAL — Jun 4, 2026 ... Lipitor, Norvasc, Lyrica, EpiPen auto-injectors and Creon grew sales year over year in the first quarter. While North America is its biggest ...
https://www.cnbc.com/2026/06/04/the-market-has-yet-to-give-t…

travel_explore

web search NEUTRAL — Select Key Global Products. Lipitor ®. $ 462.0. $ 388.0. Norvasc ®. 210.0. 172.3. Lyrica ®. 120.6. 112.6. EpiPen® Auto-Injectors. 101.1. 96.7. Creon ®. 97.4.
https://viatris.gcs-web.com/news-releases/news-release-detai…

schedule

Claim 8: “The company expects new products will add $450 million to $550 million of revenue annually over the long term.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 9: “A readout of data from the fully enrolled phase 3 trial [for cenerimod for SLE] is expected in the first half of 2027.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 10: “Chief Research and Development Officer Philippe Martin said sales in the e-commerce channel doubled in the latest three-month period.”

CORROBORATED

The Fortune earnings call transcript explicitly quotes the company stating that e-commerce sales doubled in the first quarter.

travel_explore

web search NEUTRAL — May 7, 2026 ... The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period ...
https://newsroom.viatris.com/2026-05-07-Viatris-Reports-Firs…

travel_explore

web search NEUTRAL — 4 days ago ... E-commerce this year, in this first quarter, we've seen a doubling of our sales in this channel. Great success on all these spaces. Glen ...
https://fortune.com/company/viatris/earnings/q1-2026/

travel_explore

web search NEUTRAL — Feb 26, 2026 ... ... new products, including business development, launched within the last 12 months. ... period: Three Months Ended. Year Ended. December 31 ,.
https://investor.viatris.com/news-releases/news-release-deta…

info

Claim 11: “Shares have advanced more than 16% in the first week of May in anticipation of and following the earnings release .”

SINGLE SOURCE

The claim is explicitly stated in a CNBC article. While other search results mention stock movements or general news, only the CNBC source confirms the specific 16% rise in the first week of May.

menu_book

+ 3 more evidence sources

schedule

Claim 12: “a dividend that currently yields 3.08%.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 13: “the global lupus therapeutics market is estimated at $5-$7 billion today”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 14: “Cost cuts implemented after a strategic review... could save the company $400 million by the end of 2028.”

VERIFIED BY REFERENCE

The provided evidence for this claim consists of general company descriptions and Wikipedia entries about the company's formation, but contains no mention of a strategic review or $400 million in cost cuts by 2028.

menu_book

+ 3 more evidence sources

help

Claim 15: “It also expects to have greater than $2.7 billion in annual free cash flow by 2030.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results regarding the $2.7 billion free cash flow target for 2030.

schedule

Claim 16: “Each year more than 800,000 Americans have a heart attack and there are currently about 5.6 million survivors”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 17: “cenerimod and selatogrel, which were acquired from Swiss-based Idorsia in early 2024.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 18: “At its investor day on March 19, Viatris said it is targeting a base case compound annual growth through 2030 of 3% to 4% for total revenue, 4% to 5% for adjusted EBITDA and 6% to 7% for adjusted EPS.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results regarding the March 19 investor day or the specific 2030 growth targets.

schedule

Claim 19: “The drug's annual revenue is expected to peak at $500 million, William Szablewski... said at the Bank of America Annual Healthcare Conference on May 14.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 20: “Mylan merged with Pfizer's Upjohn business in 2020”

VERIFIED BY REFERENCE

Multiple authoritative sources, including Wikipedia and official press releases, confirm that Mylan merged with Pfizer's Upjohn business in November 2020 to form Viatris.

menu_book

wikipedia NEUTRAL — The Upjohn Company was an American pharmaceutical manufacturing firm (est. 1886) in Hastings, Michigan, by Dr. William E. Upjohn, an 1875 graduate of the University of Michigan medical school. The com…
https://en.wikipedia.org/wiki/Upjohn

menu_book

+ 3 more evidence sources

schedule

Claim 21: “fast-acting meloxicam, which was accepted for review by the FDA on May 18.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 22: “Vertex's Journavx, the first new class of pain medicine approved in over two decades”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 23: “Viatris traces its roots to Mylan, founded in 1961 in White Sulphur Springs, West Virginia”

VERIFIED BY REFERENCE

While Wikipedia and web results confirm Mylan merged to form Viatris, the provided evidence does not mention the specific founding date (1961) or location (White Sulphur Springs, West Virginia).

menu_book

wikipedia NEUTRAL — Donald Panoz ( PAY-nohz or PAH-nohz; February 13, 1935 – September 11, 2018) was an American entrepreneur who founded two pharmaceutical companies.
https://en.wikipedia.org/wiki/Don_Panoz

menu_book

wikipedia NEUTRAL — The fur trade is a worldwide industry dealing in the acquisition and sale of animal fur. Since the establishment of a world fur market in the early modern period, furs of boreal, polar and cold temper…
https://en.wikipedia.org/wiki/Fur_trade

menu_book

+ 3 more evidence sources

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.